Persistent NF-κB activation in renal epithelial cells in a mouse model of HIV-associated nephropathy

American Journal of Physiology - Renal Physiology

Volumn 290, Issue 3, 2006, Pages

  Martinka, Scott ^a   Bruggeman, Leslie A ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Chronic renal disease; HIV 1; Podocyte; Transcription

Indexed keywords

ANISOMYCIN; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; DIMER; EMETINE; FLUOROURACIL; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P50; PROTEIN P52; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA; TUBULIN;

ANIMAL CELL; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENOME; GLOMERULUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOCOMPETENT CELL; IMMUNOCYTOCHEMISTRY; KIDNEY DISEASE; MOUSE; NONHUMAN; PHENOTYPE; PHOSPHORYLATION; PLASMID; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; REPORTER GENE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL; DIMERIZATION; DISEASE MODEL; KIDNEY; METABOLISM; REFERENCE VALUE; UROTHELIUM;

AIDS-ASSOCIATED NEPHROPATHY; ANIMALS; DIMERIZATION; DISEASE MODELS, ANIMAL; I-KAPPA B PROTEINS; KIDNEY; MICE; NF-KAPPA B; PHOSPHORYLATION; REFERENCE VALUES; TUBULIN; UROTHELIUM;

EID: 33645555181     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00208.2005     Document Type: Article

References (54)

1. Barisoni L, Kriz W, Mundel P, and D'Agati V. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 10: 51-61, 1999.
2. Barisoni L, Mokrzycki M, Sablay L, Nagata M, Yamase H, and Mundel P. Podocyte cell cycle regulation and proliferation in collapsing glomerulopathies. Kidney Int 58: 137-143, 2000.
3. Barisoni L and Mundel P. Podocyte biology and the emerging understanding of podocyte diseases. Am J Nephrol 23: 353-360, 2003.
4. Bird JE, Durham SK, Giancarli MR, Gitlitz PH, Pandya DG, Dambach DM, Mozes MM, and Kopp JB. Captopril prevents nephropathy in HIV-transgenic mice. J Am Soc Nephrol 9: 1441-1447, 1998.
5. Bruggeman LA, Adler SH, and Klotman PE. Nuclear factor-κB binding to the HIV-1 LTR in kidney: implications for HIV-associated nephropathy. Kidney Int 59: 2174-2181, 2001.
6. Bruggeman LA, Dikman S, Meng C, Quaggin SE, Coffman TM, and Klotman PE. Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 100: 84-92, 1997.
7. Bruggeman LA, Ross MD, Tanji N, Cara A, Dikman S, Gordon RE, Burns GC, D'Agati VD, Winston JA, Klotman ME, and Klotman PE. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol 11: 2079-2087, 2000.
8. Chen LF and Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 5: 392-401, 2004.
9. Cohen AH, Sun NC, Shapshak P, and Imagawa DT. Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy. Mod Pathol 2: 125-128, 1989.
10. DeLuca C, Roulston A, Koromilas A, Wainberg MA, and Hiscott J. Chronic human immunodeficiency virus type 1 infection of myeloid cells disrupts the autoregulatory control of the NF-κB/Rel pathway via enhanced IκBα degradation. J Virol 70: 5183-5193, 1996.
11. Dickie P, Roberts A, Uwiera R, Witmer J, Sharma K, and Kopp JB. Focal glomerulosclerosis in proviral and c-fms transgenic mice links Vpr expression to HIV-associated nephropathy. Virology 322: 69-81, 2004.
12. Eustace JA, Nuermberger E, Choi M, Scheel PJ Jr, Moore R, and Briggs WA. Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids. Kidney Int 58: 1253-1260, 2000.
13. Foo SY and Nolan GP. NF-κB to the rescue: RELs, apoptosis and cellular transformation. Trends Genet 15: 229-235, 1999.
14. Funder JW. Glucocorticoid and mineralocorticoid receptors: biology and clinical relevance. Annu Rev Med 48: 231-240, 1997.
15. Gharavi AG, Ahmad T, Wong RD, Hooshyar R, Vaughn J, Oller S, Frankel RZ, Bruggeman LA, D'Agati VD, Klotman PE, and Lifton RP. Mapping a locus for susceptibility to HIV-1-associated nephropathy to mouse chromosome 3. Proc Natl Acad Sci USA 101: 2488-2493, 2004.
16. Gherardi D, D'Agati V, Chu TH, Barnett A, Gianella-Borradori A, Gelman IH, and Nelson PJ. Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J Am Soc Nephrol 15: 1212-1222, 2004.
17. Hanna Z, Kay DG, Cool M, Jothy S, Rebai N, and Jolicoeur P. Transgenic mice expressing human immunodeficiency virus type 1 in immune cells develop a severe AIDS-like disease. J Virol 72: 121-132, 1998.
18. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, and Jolicoeur P. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 95: 163-175, 1998.
19. He JC, Husain M, Sunamoto M, D'Agati VD, Klotman ME, Iyengar R, and Klotman PE. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways. J Clin Invest 114: 643-651, 2004.
20. Heckmann A, Waltzinger C, Jolicoeur P, Dreano M, Kosco-Vilbois MH, and Sagot Y. IKK2 inhibitor alleviates kidney and wasting diseases in a murine model of human AIDS. Am J Pathol 164: 1253-1262, 2004.
21. Hiscott J, Kwon H, and Genin P. Hostile takeovers: viral appropriation of the NF-κB pathway. J Clin Invest 107: 143-151, 2001.
22. Husain M, Gusella GL, Klotman ME, Gelman IH, Ross MD, Schwartz EJ, Cara A, and Klotman PE. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 13: 1806-1815, 2002.
23. Jolicoeur P, Kay DG, Cool M, Jothy S, Rebai N, and Hanna Z. A novel mouse model of HIV-1 disease. Leukemia 13, Suppl 1: 78-80, 1999.
24. Joseph AM, Kumar M, and Mitra D. Nef: "necessary and enforcing factor" in HIV infection. Curr HIV Res 3: 87-94, 2005.
25. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, and Pestell RG. NF-κB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 12: 73-90, 2001.
26. Karn J. Tackling Tat. J Mol Biol 293: 235-254, 1999.
27. Kimmel PL. HIV-associated nephropathy: virologic issues related to renal sclerosis. Nephrol Dial Transplant 18, Suppl 6: vi59-vi63, 2003.
28. Kimmel PL, Cohen DJ, Abraham AA, Bodi I, Schwartz AM, and Phillips TM. Upregulation of MHC class II, interferon-α and interferon-γ receptor protein expression in HIV-associated nephropathy. Nephrol Dial Transplant 18: 285-292, 2003.
29. Kimmel PL, Ferreira-Centeno A, Farkas-Szallasi T, Abraham AA, and Garrett CT. Viral DNA in microdissected renal biopsy tissue from HIV infected patients with nephrotic syndrome. Kidney Int 43: 1347-1352, 1993.
30. Kopp JB, Klotman ME, Adler SH, Bruggeman LA, Dickie P, Marinos NJ, Eckhaus M, Bryant JL, Notkins AL, and Klotman PE. Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci USA 89: 1577-1581, 1992.
31. Kopp JB and Winkler C. HIV-associated nephropathy in African Americans. Kidney Int Suppl 83: S43-S49, 2003.
32. Kriz W and Lemley KV. The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 8: 489-497, 1999.
33. Lewis W. Use of the transgenic mouse in models of AIDS cardiomyopathy. AIDS 17, Suppl 1: S36-S45, 2003.
34. Marras D, Bruggeman LA, Gao F, Tanji N, Mansukhani MM, Cara A, Ross MD, Gusella GL, Benson G, D'Agati VD, Hahn BH, Klotman ME, and Klotman PE. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 8: 522-526, 2002.
35. McElhinny JA, MacMorran WS, Bren GD, Ten RM, Israel A, and Paya CV. Regulation of IκBα and p105 in monocytes and macrophages persistently infected with human immunodeficiency virus. J Virol 69: 1500-1509, 1995.
36. Mundel P, Reiser J, Zuniga Mejia BA, Pavenstadt H, Davidson GR, Kriz W, and Zeller R. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236: 248-258, 1997.
37. Nelson PJ, D'Agati VD, Gries JM, Suarez JR, and Gelman IH. Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol. J Antimicrob Chemother 51: 921-929, 2003.
38. Nelson PJ, Sunamoto M, Husain M, and Gelman IH. HIV-1 expression induces cyclin D1 expression and pRb phosphorylation in infected podocytes: cell-cycle mechanisms contributing to the proliferative phenotype in HIV-associated nephropathy. BMC Microbiol 2: e26, 2002.
39. Perkins ND, Felzien LK, Betts JC, Leung K, Beach DH, and Nabel GJ. Regulation of NF-κB by cyclin-dependent kinases associated with the p300 coactivator. Science 275: 523-527, 1997.
40. Petermann A, Hiromura K, Pippin J, Blonski M, Couser WG, Kopp J, Mundel P, and Shankland SJ. Differential expression of d-type cyclins in podocytes in vitro and in vivo. Am J Pathol 164: 1417-1424, 2004.
41. Ray PE, Bruggeman LA, Weeks BS, Kopp JB, Bryant JL, Owens JW, Notkins AL, and Klotman PE. bFGF and its low affinity receptors in the pathogenesis of HIV-associated nephropathy in transgenic mice. Kidney Int 46: 759-772, 1994.
42. Ray PE, Liu XH, Henry D III, Dye L, Xu L, Orenstein JM, and Schuztbank TE. Infection of human primary renal epithelial cells with HIV-1 from children with HIV-associated nephropathy. Kidney Int 53: 1217-1229, 1998.
43. Ray PE, Liu XH, Robinson LR, Reid W, Xu L, Owens JW, Jones OD, Denaro F, Davis HG, and Bryant JL. A novel HIV-1 transgenic rat model of childhood HIV-1-associated nephropathy. Kidney Int 63: 2242-2253, 2003.
44. Ross MD, Bruggeman LA, Hanss B, Sunamoto M, Marras D, Klotman ME, and Klotman PE. Podocan, a novel small leucine-rich repeat protein expressed in the sclerotic glomerular lesion of experimental HIV-associated nephropathy. J Biol Chem 278: 33248-33255, 2003.
45. Ross MJ and Klotman PE. HIV-associated nephropathy. AIDS 18: 1089-1099, 2004.
46. Ross MJ, Martinka S, D'Agati VD, and Bruggeman LA. NF-κB regulates Fas-mediated apoptosis in HIV-associated nephropathy. J Am Soc Nephrol 16: 2403-2411, 2005.
47. Roulston A, Lin R, Beauparlant P, Wainberg MA, and Hiscott J. Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-κB/Rel transcription factors. Microbiol Rev 59: 481-505, 1995.
48. Schwartz EJ, Cara A, Snoeck H, Ross MD, Sunamoto M, Reiser J, Mundel P, and Klotman PE. Human immunodeficiency virus-1 induces loss of contact inhibition in podocytes. J Am Soc Nephrol 12: 1677-1684, 2001.
49. Shankland SJ, Eitner F, Hudkins KL, Goodpaster T, D'Agati V, and Alpers CE. Differential expression of cyclin-dependent kinase inhibitors in human glomerular disease: role in podocyte proliferation and maturation. Kidney Int 58: 674-683, 2000.
50. Shirai A and Klinman DM. Immunization with recombinant gp160 prolongs the survival of HIV-1 transgenic mice. AIDS Res Hum Retroviruses 9: 979-983, 1993.
51. Smith MC, Austen JL, Carey JT, Emancipator SN, Herbener T, Gripshover B, Mbanefo C, Phinney M, Rahman M, Salata RA, Weigel K, and Kalayjian RC. Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy. Am J Med 101: 41-48, 1996.
52. Stevenson M. HIV-1 pathogenesis. Nat Med 9: 853-860, 2003.
53. Sunamoto M, Husain M, He JC, Schwartz EJ, and Klotman PE. Critical role for Nef in HIV-1-induced podocyte dedifferentiation. Kidney Int 64: 1695-1701, 2003.
54. Winston JA, Burns GC, and Klotman PE. Treatment of HIV-associated nephropathy. Semin Nephrol 20: 293-298, 2000.